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Introduction
Juvenile idiopathic arthritis (JIA) is a chronic autoimmune
disease of children and adolescents with primary joints
involvement and various manifestations. Uveitis is of
extra-articular signs characterized by eye inflammation.
Standard antirheumatic drugs in combination with local
therapy are effective in 60%. When these drugs are ineffec-
tive, genetically engineered drugs are used in JIA with
rheumatoid uveitis.
Objectives
This prospective observation was aimed to assessing
effectiveness and safety of adalimumab(ADA) in the
treatment of juvenile idiopathic arthritis associated with
uveitis in patients with severe JIA, prolonged disease
and resistance to standard antirheumatic therapy.
Methods
Among 27 patients with JIA and eye involvement
included in the study, 13 children had oligoarticular JIA,
8 children - polyarticular, 6 patients had systemic disease.
Study group included 20 girls and 7 boys. Mean age was
7.0 years, age of disease onset was 3.5 ± 2.07 years; mean
disease duration before ADA administration was 5 ± 3.6.
Disease onset with initial joint damage was observed in
22 children, with eye involvement - in 5 children. Prior
to ADA administration most children had high (III)
disease activity. Number of active joints was 10.8 ± 3.2,
mean ESR was 27.0 ± 13.37 mm/h, CRP – 2.25 ± 1.1
mg/dl (ref. <0.8 mg/dl). All 27 patients had active uveitis
at the moment of ADA administration. Twenty-four
(89%) patients had bilateral ocular involvement, 3 patients
(11%) - unilateral. Clinical Global Impression -Disease
Activity (VAS) score was 76.2 ± 14.0,patient/parent score
was 65.9 ± 17.1. Mean functional disability in patients
before ADA administration was 2.04 ± 0.57. Prior to
ADA administration all children received immunosup-
pressive drugs: 26 children (96%) methotrexate (MTX)
10-15mg/m2 of body surface per week, 14 children (52%)
received SandimmuneNeoral as monotherapy or in com-
bination with methotrexate, 10 children (37%) received
oral corticosteroids (CS), 27 children (100%) received
active topical treatment of uveitis.
Results
After 6 months of adalimumab therapy, humoral activity
decreasedin 24 patients (89%). ESR and CRP also substan-
tially decreased. ACRpedi-30 was achieved in 100.0%
patients, ACRpedi-50 - in 18 patients (67%), ACRpedi-70 -
in 13 children (47%). Uveitis remission was achieved in
41.2% eyes; 31.4% showed a significant reduction in
inflammatory activity, 27.4% had no significant dynamics.
After 12 months of adalimumab therapy, number of active
joints decreased from 10.8±3.2 to4.67±1.6. Mean ESR
decreased from 27.0 ± 13.37 mm/h to 6±4.9 mm/h, CRP –
from 2.25 ± 1.1 mg/dl to 0±0.34mg/dl, Clinical Global
Impression -Disease Activity (VAS) score decreased from
76.2 ± 14 to37±12.5,patient/parent score decreased from
65.9 ± 17,1 to26 ± 15. ACRpedi-30 was achieved in
100.0% patients, ACRpedi-50 - in 20 patients (74%), ACR
pedi-70 in 16 children (59.2%).
Regarding uveitis, 46,3% patients had uveitis remission,
16.7% patients–sub active process. Flares were observed in
6 patients (22,2%) often due to noncompliance of combi-
nation therapy with adalimumab and methotrexate, while
if adalimumab and methotrexate was taken according to
the recommended dosing regimen flares were observed
only in 4 patients (14,8 %).
Conclusion
Overall, treatment with adalimumab (Humira®) was
effective in the vast majority of patients with chronicDepartament of Pediatric Rheumatology, First Moscow Medical State
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